

## BENCHMARKS FOR MEASURES INCLUDED IN THE PERFORMANCE YEAR 2013 QUALITY AND RESOURCE USE REPORTS

### Administrative Claims-Based Quality Indicators

Performance Measures	2012 Mean
Osteoporosis Management in Women $\geq 67$ Who Had a Fracture	14.5%
Use of Spirometry Testing to Diagnose COPD	31.3%
Dilated Eye Exam for Beneficiaries $\leq 75$ with Diabetes	54.1%
Hba1c Testing for Beneficiaries $\leq 75$ with Diabetes	87.6%
Nephropathy Screening Test or Evidence of Existing Nephropathy for Beneficiaries $\leq 75$ with Diabetes	76.3%
Lipid Profile for Beneficiaries $\leq 75$ with Diabetes	82.3%
Lipid Profile for Beneficiaries with Ischemic Vascular Disease	78.5%
Adherence to Statin Therapy for Beneficiaries with Coronary Artery Disease	67.9%
Antidepressant Treatment for Depression	.
1. <i>Acute Phase Treatment (at least 12 weeks)</i>	58.5%
2. <i>Continuation Phase Treatment (at least 6 months)</i>	41.1%
Lipid Profile for Beneficiaries Who Started Lipid-Lowering Medications	41.4%
Breast Cancer Screening for Women Ages 40–69	62.6%
Use of High-Risk Medications in the Elderly	.
1. <i>Patients Who Receive At Least One Drug to be Avoided</i>	24.3%
2. <i>Patients Who Receive At Least Two Different Drugs to be Avoided</i>	6.9%
Lack of Monthly INR Monitoring for Beneficiaries on Warfarin	34.0%
Follow-Up After Hospitalization for Mental Illness	.
1. <i>Percentage of Patients Receiving Follow-Up Within 30 Days</i>	61.5%
2. <i>Percentage of Patients Receiving Follow-Up Within 7 Days</i>	35.1%

### Care Coordination Quality Indicators

Performance Measures		2012 Mean
CMS-1	Acute Conditions Composite*	8.4
.	<i>PQI-11 Bacterial Pneumonia*</i>	12.4
.	<i>PQI-12 Urinary Tract Infection*</i>	8.1
.	<i>PQI-10 Dehydration*</i>	4.6
CMS-2	Chronic Conditions Composite*	54.0
.	<i>Diabetes (composite of 4 indicators)*</i>	18.9
.	<i>PQI-5 COPD or Asthma*</i>	78.1
.	<i>PQI-8 Heart Failure*</i>	100.7
CMS-3	All-Cause Hospital Readmissions	16.4%

\* Rate per 1,000 beneficiaries

**Physician Quality Reporting System (PQRS) Quality Indicators for Groups that Participated in the Group Practice Reporting Option (GPRO)**

<b>Performance Measures</b>		<b>2012 Mean</b>
.	CAD Composite (All or Nothing Scoring)	63.6%
.	<i>CAD-2 CAD: Lipid Control</i>	54.1%
.	<i>CAD-7 CAD: ACE Inhibitor or ARB Therapy for Patients with CAD and Diabetes and/or LVSD</i>	63.0%
Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	76.0%
Care-2	Falls: Screening for Future Fall Risk	32.6%
DM-2	DM: Hemoglobin A1c Poor Control in DM (> 9.0)	21.4%
.	DM Composite (All or Nothing Scoring)	23.2%
.	<i>DM-13 DM: High Blood Pressure Control</i>	66.8%
.	<i>DM-14 DM: LDL-C Control</i>	54.0%
.	<i>DM-15 DM: Hemoglobin A1c Control (&lt; 8.0)</i>	65.3%
.	<i>DM-16 DM: Daily Aspirin Use for Patients with Diabetes and Ischemic Vascular Disease</i>	70.8%
.	<i>DM-17 DM: Tobacco Non-Use</i>	72.3%
HF-6	HF: Beta Blocker Therapy for LVSD	82.0%
HTN-2	HTN: Controlling High Blood Pressure	65.0%
IVD-1	IVD: Complete Lipid Profile and LDL-C Control	46.3%
IVD-2	IVD: Use of Aspirin or Another Antithrombotic	62.4%
Prev-5	Prev: Screening Mammography	48.3%
Prev-6	Prev: Colorectal Cancer Screening	40.5%
Prev-7	Prev: Influenza Immunization	38.9%
Prev-8	Prev: Pneumonia Vaccination for Patients ≥ 65	45.4%
Prev-9	Prev: BMI Screening and Follow-Up	49.1%
Prev-10	Prev: Tobacco Use: Screening and Cessation Intervention	79.6%
Prev-11	Prev: Screening for High Blood Pressure	90.6%
Prev-12	Prev: Screening for Clinical Depression and Follow-Up Plan	22.3%

Note: PQRS GPRO and ACO GPRO measures are the same in 2013.

**Physician Quality Reporting System (PQRS) Quality Indicators for Groups That Did Not Participate in the Group Practice Reporting Option (GPRO)**

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
1	Diabetes Mellitus (DM): Hemoglobin A1c Poor Control in Diabetes Mellitus	21.4%
2	Diabetes Mellitus (DM): Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	48.7%
3	Diabetes Mellitus (DM): High Blood Pressure Control in Diabetes Mellitus	68.6%
5	Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	77.0%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	74.8%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)	65.6%
8	Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	82.0%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	44.0%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	68.3%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	96.7%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	97.1%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	97.5%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	93.2%
20	Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician	96.9%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	95.3%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	97.3%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	97.3%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	58.9%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	85.6%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	94.0%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	83.4%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	86.2%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	88.6%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	73.3%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	82.1%

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	24.1%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	15.2%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	70.9%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	99.3%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	96.6%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	99.4%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	76.0%
47	Advance Care Plan	56.3%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	47.6%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	89.5%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	97.0%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	75.5%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	99.0%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	.
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	97.0%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	97.2%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	97.6%
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	96.9%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	98.4%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	96.0%
64	Asthma: Assessment of Asthma Control	.
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	47.0%
66	Appropriate Testing for Children with Pharyngitis	.
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	96.8%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	98.7%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	86.9%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	96.3%

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	95.9%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	94.3%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	79.6%
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	.
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	.
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	.
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	.
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	.
86	Hepatitis C: Antiviral Treatment Prescribed	.
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	.
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	77.3%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	.
91	Acute Otitis Externa (AOE): Topical Therapy	91.7%
92	Acute Otitis Externa (AOE): Pain Assessment	87.9%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	90.3%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	98.1%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	98.0%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	.
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	87.1%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	99.4%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	76.7%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	91.4%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	77.7%
109	Osteoarthritis (OA): Function and Pain Assessment	90.0%
110	Preventive Care and Screening: Influenza Immunization	38.9%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	45.4%
112	Preventive Care and Screening: Screening Mammography for Women Aged 40 - 69	48.3%
113	Preventive Care and Screening: Colorectal Cancer Screening	40.5%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	.

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
117	Diabetes Mellitus (DM): Dilated Eye Exam in Diabetic Patients	89.4%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	63.0%
119	Diabetes Mellitus (DM): Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	81.9%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	45.6%
122	Adult Kidney Disease: Blood Pressure Management	81.5%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	20.1%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records	99.6%
126	Diabetic Mellitus (DM): Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	83.0%
127	Diabetic Mellitus (DM): Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	88.0%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	49.1%
130	Documentation of Current Medications in the Medical Record	82.7%
131	Pain Assessment and Follow-Up	82.1%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	64.2%
137	Melanoma: Continuity of Care - Recall System	97.7%
138	Melanoma: Coordination of Care	94.3%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	93.3%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	95.5%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	71.2%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	.
144	Oncology: Medical and Radiation - Plan of Care for Pain	.
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	67.1%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	2.4%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	62.3%
148	Back Pain: Initial Visit	.
149	Back Pain: Physical Exam	.
150	Back Pain: Advice for Normal Activities	.
151	Back Pain: Advice Against Bed Rest	.
154	Falls: Risk Assessment	76.5%
155	Falls: Plan of Care	92.2%

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
156	Oncology: Radiation Dose Limits to Normal Tissues	97.4%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	.
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	97.3%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	.
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	.
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	.
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	.
163	Diabetic Mellitus (DM): Foot Exam	60.2%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	.
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	.
166	Coronary Artery Bypass Graft (CABG): Stroke	.
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	.
168	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration	.
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	.
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	.
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	.
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	96.5%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	54.6%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	91.1%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	97.3%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	89.8%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	97.6%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	99.6%
181	Elder Maltreatment Screen and Follow-Up Plan	99.3%
182	Functional Outcome Assessment	69.0%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	67.3%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	69.6%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	98.1%
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	97.1%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	.
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	.
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	.



PQRS Performance Measures	2012 Mean
190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	.
191 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery	93.2%
192 Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	8.7%
193 Perioperative Temperature Management	92.7%
194 Oncology: Cancer Stage Documented	95.6%
195 Radiology: Stenosis Measurement in Carotid Imaging Reports	71.4%
196 Coronary Artery Disease (CAD): Symptom and Activity Assessment	61.0%
197 Coronary Artery Disease (CAD): Lipid Control	54.1%
198 Heart Failure (HF): Left Ventricular Ejection Fraction (LVEF) Assessment	78.7%
200 Heart Failure (HF): Warfarin Therapy for Patients with Atrial Fibrillation	54.6%
201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	67.5%
204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	62.4%
205 HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	.
206 HIV/AIDS: Screening for High Risk Sexual Behaviors	.
207 HIV/AIDS: Screening for Injection Drug Use	.
208 HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	.
209 Functional Communication Measure - Spoken Language Comprehension for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
210 Functional Communication Measure - Attention for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
211 Functional Communication Measure - Memory for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
212 Functional Communication Measure - Motor Speech for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
213 Functional Communication Measure - Reading for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
214 Functional Communication Measure - Spoken Language Expression for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
215 Functional Communication Measure - Writing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
216 Functional Communication Measure - Swallowing for Patients with Diagnosis of Late Effects of Cerebrovascular Disease (CVD)	.
217 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	.
218 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	.
219 Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	.

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	67.1%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	.
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	.
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs or Other General Orthopedic Impairments	.
224	Melanoma: Overutilization of Imaging Studies in Melanoma	99.4%
225	Radiology: Reminder System for Mammograms	80.0%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	79.6%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	85.0%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	.
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	.
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	.
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)	.
235	Hypertension (HTN): Plan of Care	74.4%
236	Hypertension (HTN): Controlling High Blood Pressure	65.0%
237	Hypertension (HTN): Blood Pressure Measurement	95.4%
238	Drugs to Be Avoided in the Elderly	14.0%
239	Weight Assessment and Counseling for Children and Adolescents	.
240	Childhood Immunization Status	.
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	46.3%
242	Coronary Artery Disease (CAD): Symptom Management	0.1%
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	.
244	Hypertension (HTN): Blood Pressure Management	.
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers (Overuse Measure)	.
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers (Overuse Measure)	.
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	.
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	.
249	Barrett's Esophagus	99.2%
250	Radical Prostatectomy Pathology Reporting	99.3%

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing for Breast Cancer Patients	97.3%
252	Anticoagulation for Acute Pulmonary Embolus Patients	85.0%
253	Pregnancy Test for Female Abdominal Pain Patients	68.1%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	.
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	.
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	.
257	Statin Therapy at Discharge After Lower Extremity Bypass (LEB)	.
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	.
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	.
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients without Major Complications (Discharged to Home by Post-Operative Day #2)	.
261	Referral to Otologic Evaluation for Patients with Acute or Chronic Dizziness	.
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	99.2%
263	Preoperative Diagnosis of Breast Cancer	98.7%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	94.4%
265	Biopsy Follow-Up	86.2%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	96.9%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	96.4%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	.
269	Inflammatory Bowel Disease (IBD): Type, Anatomic Location and Activity All Documented	.
270	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy	.
271	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury - Bone Loss Assessment	.
272	Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization	.
273	Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization	.
274	Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	.
275	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy	.
276	Sleep Apnea: Assessment of Sleep Symptoms	.
277	Sleep Apnea: Severity Assessment at Initial Diagnosis	.
278	Sleep Apnea: Positive Airway Pressure Therapy Prescribed	.

<b>PQRS Performance Measures</b>		<b>2012 Mean</b>
279	Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy	.
280	Dementia: Staging of Dementia	.
281	Dementia: Cognitive Assessment	.
282	Dementia: Functional Status Assessment	.
283	Dementia: Neuropsychiatric Symptom Assessment	.
284	Dementia: Management of Neuropsychiatric Symptoms	.
285	Dementia: Screening for Depressive Symptoms	.
286	Dementia: Counseling Regarding Safety Concerns	.
287	Dementia: Counseling Regarding Risks of Driving	.
288	Dementia: Caregiver Education and Support	.
289	Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review	.
290	Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment	.
291	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment	.
292	Parkinson's Disease: Querying about Sleep Disturbance	.
293	Parkinson's Disease: Rehabilitative Therapy Options	.
294	Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed	.
295	Hypertension (HTN): Appropriate Use of Aspirin or Other Antiplatelet or Anticoagulant Therapy	.
296	Hypertension (HTN): Complete Lipid Profile	.
297	Hypertension (HTN): Urine Protein Test	.
298	Hypertension (HTN): Annual Serum Creatinine Test	.
299	Hypertension (HTN): Diabetes Mellitus Screening Test	.
300	Hypertension (HTN): Blood Pressure Control	.
301	Hypertension (HTN): Low Density Lipoprotein (LDL-C) Control	.
302	Hypertension (HTN): Dietary and Physical Activity Modifications Appropriately Prescribed	.
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	.
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	.
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	.
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	.
307	Prenatal Care: Anti-D Immune Globulin	.
308	Smoking and Tobacco Use Cessation, Medical Assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	5.0%
309	Cervical Cancer Screening	32.3%
310	Chlamydia Screening for Women	.

PQRS Performance Measures	2012 Mean
311 Use of Appropriate Medications for Asthma	83.0%
312 Low Back Pain: Use of Imaging Studies	15.6%
313 Diabetes Mellitus (DM): Hemoglobin A1c Control (< 8%)	55.0%
316 Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL	51.7%
317 Preventive Care and Screening: Screening for High Blood Pressure	90.6%

Note: Benchmarks are not available for measures where fewer than twenty groups reported at least twenty cases.

## Narrative Specifications

1. Performance rates for the claims-based quality indicators, all cause readmission, and ambulatory care sensitive condition measures were computed:
  - a. Using performance year 2012 data and 2012 measure specifications.
    - i. Narrative specifications for the claims-based quality indicators can be found at <http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2012-QualityMeasures-QRUR.pdf>
    - ii. Narrative specifications for the ACSC and ACR measures can be found at <http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/2012-ACSC-Outcomes-Msrs.pdf>.
  - b. For all medical group practices (identified by Tax Identification Number, or TIN) with at least one eligible professional (EP). Beneficiaries were attributed to TINs using the same approach as the Medicare Shared Savings Program attribution methodology that was used for the 2012 Quality and Resource Use Reports (QRURs).
2. EP PQRS performance rates were “rolled up” to the TIN level.
  - a. Only performance rates for incentive eligible EPs were included.
  - b. EHR records with a performance rate of 0 or a case size of 0 were not included.
  - c. For a given measure, all available submission mechanisms (i.e. claims, registry, EHR, or measures group) were included.
  - d. If a TIN-EP reported a performance rate for a measure under multiple mechanisms, then the mechanism associated with the highest performance rate was selected.
  - e. For each TIN and measure, rates were rolled up to the TIN level as follows:
    - i. For all TIN-EPs reporting the measure, the TIN-EP performance rate was multiplied by the denominator cases. The TIN numerator was then calculated as the sum across all TIN-EPs reporting the measure.
    - ii. For all TIN-EPs reporting the measure, the TIN denominator was calculated as the sum of the denominator cases for the measure. Each TIN’s performance rate on the measure was calculated as the TIN numerator divided by the TIN denominator.

3. Benchmark means were computed as the case-weighted average across all TINs with at least twenty cases.
  - a. PQRS GPRO, ACO, and EP rates for satisfactory reporters were combined according to Table 1.
    - i. Benchmarks for EP PQRS measures were not created if less than twenty groups reported at least twenty cases.
  - b. For each measure, each TIN's weight was the number of cases for the TIN divided by the total number of cases for the measure.
  - c. The case-weighted mean was computed by multiplying the performance rate for each TIN by its weight and then summing all terms.

**Table 1. GPRO, ACO, and EP PQRS Mapping**

<b>PQRS GPRO</b>	<b>ACO GPRO</b>	<b>EP PQRS #</b>
Care-1	Care-1	46
Care-2	Care-2	.
.	CAD	.
	Composite	
CAD-2	CAD-2	197
CAD-7	CAD-7	118
DM-2	DM-2	1
.	DM	.
	Composite	
.	DM-13	.
.	DM-14	.
.	DM-15	.
.	DM-16	.
.	DM-17	.
HF-6	HF-6	8
HTN-2	HTN-2	236
IVD-1	IVD-1	241
IVD-2	IVD-2	204
Prev-5	Prev-5	112
Prev-6	Prev-6	113
Prev-7	Prev-7	110
Prev-8	Prev-8	111
Prev-9	Prev-9	128
Prev-10	Prev-10	226
Prev-11	Prev-11	317
.	Prev-12	.